a The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes , National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel , Petah Tikva , Israel.
b Sackler Faculty of Medicine , Tel Aviv University , Tel Aviv , Israel.
Endocr Res. 2019 Feb-May;44(1-2):16-26. doi: 10.1080/07435800.2018.1493598. Epub 2018 Jul 6.
To investigate the effect of growth hormone (GH) therapy on appetite-regulating hormones and to examine the association between these hormones and the response to GH, body composition, and resting energy expenditure (REE).
Nine pre-pubertal children with idiopathic short stature underwent a standard meal test before and 4 months following initiation of GH treatment. Ghrelin, GLP-1, leptin, and insulin levels were measured; area under the curve (AUC) was calculated. Height, weight, body composition, REE, and insulin-like growth factor levels were recorded at baseline and after 4 and 12 months.
Following 4 months of GH therapy, food intake increased, with increased height-standard deviation score (SDS), weight-SDS, and REE (p < .05). Significant changes in appetite-regulating hormones included a decrease in postprandial AUC ghrelin levels (p = .045) and fasting GLP-1 (p = .038), and an increase in fasting insulin (p = .043). Ghrelin levels before GH treatment were positively correlated with the changes in weight-SDS (fasting: r = .667, p = .05; AUC: r = .788, p = .012) and REE (fasting: r = .866, p = .005; AUC: r = .847, p = .008) following 4 months of GH therapy. Ghrelin AUC at 4 months was positively correlated with the changes in height-SDS (r = .741, p = .022) and fat-free-mass (r = .890, p = .001) at 12 months of GH treatment.
The reduction in ghrelin and GLP-1 following GH treatment suggests a role for GH in appetite regulation. Fasting and meal-AUC ghrelin levels may serve as biomarkers for predicting short-term (4 months) changes in weight and longer term (12 months) changes in height following GH treatment. The mechanisms linking GH with changes in appetite-regulating hormones remain to be elucidated.
SDS: standard deviation score; REE: resting energy expenditure; SMT: standard meal test; AUC: area under the curve; ISS: idiopathic short stature; SGA: small for gestational age; FFM: fat-free-mass; FM: fat mass; EER: estimated energy requirements; DRI: dietary reference intakes; IQR: inter-quartile range.
研究生长激素(GH)治疗对食欲调节激素的影响,并探讨这些激素与 GH 反应、身体成分和静息能量消耗(REE)之间的关系。
9 名患有特发性身材矮小的青春期前儿童在开始 GH 治疗前和治疗后 4 个月进行标准餐测试。测量了 ghrelin、GLP-1、瘦素和胰岛素水平;计算了曲线下面积(AUC)。在基线和治疗后 4 个月和 12 个月时记录了身高、体重、身体成分、REE 和胰岛素样生长因子水平。
在 GH 治疗 4 个月后,进食量增加,身高标准差评分(SDS)、体重 SDS 和 REE 增加(p <.05)。食欲调节激素的显著变化包括餐后 AUC ghrelin 水平下降(p =.045)和空腹 GLP-1 下降(p =.038),以及空腹胰岛素增加(p =.043)。GH 治疗前的 ghrelin 水平与治疗后 4 个月时体重 SDS 的变化呈正相关(空腹:r =.667,p =.05;AUC:r =.788,p =.012)和 REE(空腹:r =.866,p =.005;AUC:r =.847,p =.008)。4 个月时的 ghrelin AUC 与治疗 12 个月时身高 SDS(r =.741,p =.022)和无脂肪质量(r =.890,p =.001)的变化呈正相关。
GH 治疗后 ghrelin 和 GLP-1 的减少表明 GH 在食欲调节中起作用。空腹和餐时 AUC ghrelin 水平可作为预测 GH 治疗后短期(4 个月)体重变化和长期(12 个月)身高变化的生物标志物。GH 与食欲调节激素变化之间的联系机制仍有待阐明。